TP53 and B-cell chronic lymphocytic leukemia: Similar findings were reported from a pooled analysis of four clinical trials where ibrutinib ± rituximab was used in the management of CLL patients with TP53 disruption (n = 89); the 4-year PFS was 79%, and 4-year OS was 88% [31].